Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This open-label Phase 2 study will evaluate the safety and efficacy of weekly 2.0 mg/kg/wk
infusions of BMN 110 in pediatric patients, less than 5 years of age at the time of
administration of the first dose of study drug, diagnosed with MPS IVA (Morquio A Syndrome)
for up to 208 weeks.